Biogen Idec Says Long-Lasting Hemophilia Drug Meets Safety Goals

Biogen Idec (BIIB) and Swedish Orphan Biovitrum said a potential hemophilia B treatment has metsafety goals in an early-stage study.

The study involved 14 previously treated patients, and the data showed that the drug, rFIXFc, was well tolerated and demonstrated an approximately three-fold increase in half-life, compared to previous data for existing therapies. That would give provide prolonged protection with a single dose.

The study was presented at the World Federation of Hemophilia Congress in Buenos Aires, Argentina, on July 11, 2010. Based on this study, the companies said they'll conduct a global registrational trial of the safety and effectiveness of the drug with 75 patients.

Hemophilia is a rare, inherited disorder in which patients have an impaired ability for blood clotting, leading to excessive bleeding. Current treatments require intravenous injections twice a week. This drug, the companies hope, would reduce the injections to once a week.

Read Full Story

Markets

DJIA 21,674.51 -76.22 -0.35%
NASDAQ 6,216.53 -5.39 -0.09%
S&P 500 2,425.55 -4.46 -0.18%
NIKKEI 225 19,470.41 -232.22 -1.18%
HANG SENG 27,047.57 -296.65 -1.08%
DAX 12,165.19 -38.27 -0.31%
USD (per EUR) 1.18 0.00 0.40%
USD (per CHF) 0.96 0.00 0.29%
JPY (per USD) 109.20 -0.12 -0.11%
GBP (per USD) 1.29 0.00 0.08%

Can't get enough business news?

Sign up for Finance Report by AOL and get everything from retailer news to the latest IPOs delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.